REM Analytics SA

REM Analytics SA is a biotechnology company spun out from EPFL in 2020, based at the BioArk in Monthey, Switzerland. The company develops high-resolution microbiome assays and testing services with species-to-strain level quantification across different type of matrices, including gut and vaginal.

The proprietary ATGC platform combines Cycling Temperature Capillary Electrophoresis with curated reference databases and specialised bioinformatics. Validated panels include a CE-IVD marked vaginal microbiome panel and a Bifidobacterium subspecies panel for gut health research.

REM offers end-to-end management of microbiome-focused clinical studies, from protocol design and ethics submission through to analysis and publication, using validated at-home collection kits and a dedicated participant app that supports remote sample collection and patient engagement over extended follow-up periods.

REM is active in Horizon Europe consortia and Innosuisse programmes and is open to partnerships with pharma and biotech companies, clinical research organisations and academic groups for collaborative studies, custom assay co-development and multi-partner grant applications on microbiome-based cancer prediction and prognosis.